Managed Care Pharmacy and Medical Drug Policies

In accordance with La. R.S. 46:460.51, et seq., prior to adopting, approving, amending, or implementing certain policies or procedures, LDH will publish the proposed policy or procedure for the purpose of soliciting public comments. For this purpose, a policy or procedure, as defined by the statute, shall mean a requirement governing the administration of managed care organizations specific to billing guidelines, medical management and utilization review guidelines, case management guidelines, claims processing guidelines and edits, grievance and appeals procedures and process, other guidelines or manuals containing pertinent information related to operations and pre-processing claims, and core benefits and services.

The following table contains the LDH and managed care organization pharmacy and medical drug policies that are open for public comment. To provide feedback, please complete this form. Refer to the links below the table for archived postings and public comments.

Item Number	Policy/Procedure Date Posted Comment Period Closed Status	Date Posted	Comment Period Closed Status	Status	Document Links
2026-HB-MED-678	Lerochol	7/7/26	8/21/26	Pending	Lerochol
2026-LHCC-MED-1013	Atezolizumab (Tecentriq)	6/4/26	7/19/26	Pending	Atezolizumab (Tecentriq)
2026-LHCC-MED-1012	Paclitaxel, Protein-Bound (Abraxane)	6/4/26	7/19/26	Pending	Paclitaxel, Protein-Bound (Abraxane)
2026-LHCC-MED-1011	Nivolumab (Opdivo)	6/4/26	7/19/26	Pending	Nivolumab (Opdivo)
2026-LHCC-MED-1010	Mitoxantrone	6/4/26	7/19/26	Pending	Mitoxantrone
2026-LHCC-MED-1009	Ado-Trastuzumab Emtansine (Kadcyla)	6/4/26	7/19/26	Pending	Ado-Trastuzumab Emtansine (Kadcyla)
2026-LHCC-MED-1008	Revakinagene taroretcel-lwey  (Encelto)	6/4/26	7/19/26	Pending	Revakinagene taroretcel-lwey  (Encelto)
2026-LHCC-MED-1007	Remestemcel-L-rknd (Ryoncil)	6/4/26	7/19/26	Pending	Remestemcel-L-rknd (Ryoncil)
2026-LHCC-MED-1006	Ciltacabtagene Autoleucel (Carvykti)	6/4/26	7/19/26	Pending	Ciltacabtagene Autoleucel (Carvykti)
2026-LHCC-MED-1005	Obinutuzumab (Gazyva)	6/4/26	7/19/26	Pending	Obinutuzumab (Gazyva)
2026-LHCC-MED-1004	Pegunigalsidase alfa-iwxj (Elfabrio)	6/4/26	7/19/26	Pending	Pegunigalsidase alfa-iwxj (Elfabrio)
2026-LHCC-MED-1003	Desmopressin Acetate (DDAVP)	6/4/26	7/19/26	Pending	Desmopressin Acetate (DDAVP)
2026-LHCC-MED-1002	Efgartigimod Alfa-fcab (Vyvgart)	6/4/26	7/19/26	Pending	Efgartigimod Alfa-fcab (Vyvgart)